Aim: To investigate the antitumor activity and safety of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand (rmh TRAIL). Methods: Antitumor activity of rmh TRAIL was evaluated by using several tumor cell lines by MTT assay in vitro, and by using a mouse xenograft model in vivo. rmh TRAIL-induced apoptosis in tumor cells was detected by cell death enzyme-linked immunosorbent assay (ELISA), TdT-mediated dUTP nickend labeling (TUNEL) assay and flow cytometry. The safety of rmh TRAIL was also evaluated in several normal human cell lines. Results: At the concentration of 0.32-1 000 ng/mL, rmh TRAIL remarkably inhibited the proliferation of 5 tumor cell lines from lung, colon, and breast cancer compared with wild type (wt TRAIL) in vitro, whereas at the concentration of 1 ng/mL-10 µg/mL, rmh TRAIL showed no or mild cytotoxicity in the normal cell lines. rmh TRAIL (3, 15 mg/kg, ip, once daily for 10 d) exerted a significant inhibition on the growth of xenograft tumor NCI-H460 in nude mice compared with the saline group (P<0.01), and was more potent than wt TRAIL, a positive control. The apoptosis of NCI-H460 cells was markedly induced in a concentration-dependent and time-dependent manner after rmh TRAIL treatment. The percentage of apoptotic cells induced by rmh TRAIL in NCI-H460 cells was significantly higher than that by wt TRAIL. Conclusion: rmh TRAIL provided potent antitumor activity in vivo and in vitro, whereas most normal human cells were resisitant to rmh TRAIL. The results suggested that rmh TRAIL might be a useful anticancer agent in future.
Introduction
Apoptosis, or programmed cell death, is a regulated process that is essential to metazoan development and tissue homeostasis [1] . Instructive apoptosis plays a physiological role in deletion of activated lymphocytes at the end of an immune response and in elimination of virus-infected cells and oncogenically transformed cells. Deregulation of programmed cell death leads to several human diseases, including cancer, neurodegenerative disorders, and acquired immunodeficiency syndrome [2] . Since the 1980s, biotherapy has become an important modality for treating cancer [3] . Biotherapy is achieved by inducing apoptosis of tumor cells, which is the ultimate objective of tumor therapy. The members of the tumor necrosis factor (TNF) family became the focus of biotherapy of cancer [4] . Despite the potential of TNF and Fas ligand (FasL; also called CD95L) to induce apoptosis in many types of tumor cells, severe toxic sideeffects preclude both of these ligand from use in systemic anticancer therapy [5, 6] . TNF infusion causes a lethal inflammatory response that resembles septic shock mediated by activation of the proinflammatory transcription factor NF-kappaB in vascular endothelial cells and macrophages. Infusion of agonistic anti-Fas antibody causes lethal liver damage as a result of the induction of Fas-dependent apoptosis in hepatocytes. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, also called Apo2 ligand) is a newly discovered TNF superfamily member initially cloned from human heart and lymphocyte cDNA libraries because of its sequence homology to TNF and FasL [7, 8] . The TRAIL mRNA is constructively expressed at significant levels in many tissues in humans (eg lung, liver, spleen, kidney, thymus, prostate, ovary, intestine, periphero-lymphoid nodes, heart, placenta, and skeletal muscle). Recent studies have shown that TRAIL could induce apoptosis in numerous transformed cell lines of different lineage, but showed nontoxicity systemically unlike TNF and FasL, ionizing radiation and chemotherapy [9] [10] [11] . The combination of TRAIL and ionizing radiation or chemotherapy appears to have an enhancing effect on cancer therapy, and consequently reduces the dose and side-effects of chemotherapeutants [12] [13] [14] [15] [16] . Therefore, TRAIL is considered to be the most promising among antitumor agents at present.
TRAIL is expressed as a type II transmembrane protein, as are other members TNF and FasL [8] , and its extracellular region forms a soluble molecule upon cleavage [17] . There are several forms of recombinant TRAIL: soluble TRAIL fusion protein (termed LZ-TRAIL) in which the extracellular region of the ligand (amino acids 95-281) is linked to an exogenous, modified leucine zipper that drives trimerization [11] ; soluble TRAIL containing just the extracellular region (amino acids 114-281); polyhistidine-tagged soluble form (his-TRAIL, amino acids 114-281) [8, 18] ; glutathione S-transferase-TRAIL (GST-TRAIL, amino acids 95-281); and flag epitope-tagged form (amino acids 95-281) [8, 18] . However, these other forms have deficiencies in solubility, antitumor activity and security. Therefore, Beijing Sunbio Biotech developed recombinant mutant human TRAIL (rmh TRAIL). The aim of the present work was to evaluate the antitumor activity of rmh TRAIL in vitro and in vivo, and to explore its antitumor mechanism. Cell growth inhibition assay The cytotoxicity of the rmh TRAIL and wt TRAIL was determined using a colorimetric MTT assay. Cells in the logarithmic growth phase were dispersed to prepare a suspension of cell density of 6×10 . Then cell suspension was seeded in a 96-well plate in total volume of 100 µL per well and incubated in a 5% CO 2 atmosphere at 37 °C for 24 h. Then, the supernatant was removed and the cells were added with 100 µL of different concentrations of the drugs followed by incubation at 37 °C for another 24 or 72 h. For controls, cells were placed in medium only. After removal of the supernatant, the cells were treated with 5.0 g/L MTT for 4 h, the purple blue sediment was dissolved in 150 µL Me 2 SO, and the absorbance at 490 nm was measured using a microplate reader (BIO-RAD, Hercules, USA, model 550). The survival rate of cell growth was calculated using the following formula:
Materials and methods

Expression and purification of protein
Survival rate (%)=A 490 (drug)/A 490 (control)×100%. Triplicate wells were analyzed for each concentration.
The 50% inhibitory concentration (IC 50 ) is the concentration required for 50% inhibition, which is calculated from the linear equation, which was educed by concentration versus survival rate regression curve. The experiments were performed in triplicates.
Mouse xenograft tumor model According to the protocol of transplantation tumor research [19] , NCI-H460 tumor tissues were chopped into 2 mm , the 32 tumor-grafted mice were randomly divided into 4 groups (n=8); that is, negative control group (treated with normal saline), positive control group (wt TRAIL, 15 mg/kg) and rmh TRAIL treated groups (3 and 15 mg/kg). All drugs or saline were injected ip once daily for 10 d followed by another 14 d observation.
The tumor volume (TV) was calculated using the following formula:
TV=1/2×a×b 2 (in which a is the length and b is the width of tumor).
The evaluation index of anti-tumor activity was relative tumor weight inhibition ratio (%), which was calculated by the following formula:
Tumor weight inhibition ratio (%)=(1-T/C)×100% (T: test group's or positive control group's mean tumor weight; C: negative control group's mean tumor weight).
The data were then subjected to a statistical analysis (t-test) for actual efficiency of the material tested.
Assessment of apoptosis Various methods, described below, were used to evaluate NCI-H460 apoptosis.
(a) DNA fragmentation detection by ELISA A cell death detection ELISA kit was used according to the manufacturer's instructions for DNA fragment detection [20] . The DNA fragments are discrete multiples of a 180-200 bp subunit, which can be detected as a DNA ladder on agarose gel. The enrichment of mono-and oligonucleosomes in the cytoplasm of the apoptotic cells is a result of DNA degradation that occurs several hours before plasma membrane breakdown. The principle on which this test is based is the detection of mono-and oligonucleosomes in the cytoplasmic fractions of cell lysates by using biotinylated antihistoneand peroxidase-coupled anti-DNA antibodies. The enrichment of mono-and oligonucleosomes released into the cytoplasm is calculated as the ratio of absorbance of sample cells to absorbance of control cells. The enrichment factor was used as a parameter of apoptosis and is shown on the Y axis as mean±SD of triplicate experiments performed in triplicates. An enrichment factor of 1 represents spontaneous apoptosis. NCI-H460 were grown in 96-well plates and exposed to rmhTRAIL 10 ng/mL for 0.5 to 4 h or 0.0128 ng/mL to 40 ng/mL for 2 h.
(b) TdT-mediated dUTP nick-end labeling (TUNEL) assay After incubated with 15 ng/mL rmh TRAIL for 1, 2, and 4 h, NCI-H460 cells were smeared on slides, fixed by 4% paraformaldehyde in PBS (pH 7.2) for 30 min at room temperature, washed 3 times with PBS, and blocked by 0.3% H 2 O 2 . Then, cells were permeabilized on ice using 0.3% Triton X-100 in PBS for 2 min. Subsequent operations were refered to the manufacturer's instruction of In situ cell death detection kit and DAB kit. The samples were dehydrated by ethanol and cleared in dimethylbenzene, analyzed by microscopy and photos were taken using a Nikon 4 500 digital camera.
(c) Flow cytometry For apoptotic cell detection analysis, NCI-H460 cells were treated with rmh TRAIL or wt TRAIL (1, 10, and 100 ng/mL) for 12 h. All of the attached and the detached cells were harvested. Detection of the apoptotic cells was referred to the manufacturer's instruction of Annexin V-FITC apoptosis detection kit. Statistical analysis Data were expressed as mean±SD. Data of the representatives were analyzed for statistical significance using a t-test. P<0.05 was considered statistically significant.
Results
Various tumor cell lines are sensitive to rmh TRAILinduced death in vitro To explore the antitumor activity of rmh TRAIL against a spectrum of cancer cell lines, we tested its effect in vitro on the inhibition of 5 different cell lines derived from cancers of the lung, colon, and breast (2 lung cancer cell lines, 2 breast cancer cell lines, and 1 colon cancer cell line) by MTT assay. rmh TRAIL exerted a cytotoxic effect on these cell lines and inhibited cell growth after cells being treated for 24 h or 72 h. Furthermore, the antitumor activity of rmh TRAIL was notably higher than that of wt TRAIL, and IC 50 for rmh TRAIL against all cell lines were significantly lower than wt TRAIL (Table 1, Antitumor activity of rmh TRAIL in a mouse xenograft study To determine whether the tumoricidal activity of rmh TRAIL observed in vitro could be demonstrated in vivo, BALB/c nude mice were transplanted sc with NCI-H460 tumor tissue, which showed intermediate sensitivity to rmh TRAIL in vitro (Table 1) , and allowed tumors to establish. The tumors in the control group grew steadily in an exponential manner. wt TRAIL treatment gave a 25.7% reduction in mean tumor volume, which was lower than that of rmh TRAIL. In contrast, the rmh TRAIL treated groups showed a marked reduction in tumor size, especially during the treatment period ( Figure 2 , Table 2 ). The tumors in some Table 2 ).
Apoptosis induced by rmh TRAIL a.rmh TRAIL-induced cell death of NCI-H460 cells detected by ELISA rmh TRAIL 10 ng/mL was chosen for DNA fragmentation experiment by ELISA at different time points. This concentration of rmh TRAIL-induced apoptosis showed a time-dependent manner. At 2 and 4 h after treatment, rmh TRAIL induced a significant increase of cytoplasmic nucleosomes ( Figure 3A) . The result accords with agarose gel electrophoesis result (data not shown). More-over, we examined different concentrations (from 0.0128 ng/mL to 40 ng/mL) of rmh TRAIL-induced apoptosis for 2 h. The result showed a dose-dependent manner ( Figure 3B ). b. TUNEL assay The pictures displayed in the Figure  4 were taken after incubation with rmh TRAIL 15 ng/mL for 1, 2, and 4 h. The nucleus condensation and segmentation were observed by microscope. Lots of apoptotic bodies were found in rmh TRAIL-treated cells but none in untreated cells.
c. Flow cytometry To confirm that the percentage of apoptosis induced by various concentration of rmh TRAIL in NCI-H460 cells, Annexin V and PI double staining and flow cytometry were performed. The percentages of apoptosis induced by rmh TRAIL and wt TRAIL (1 ng/mL, 10 ng/mL, 100 ng/mL) for 12 h were 8.11%, 32.80%, 59.68% and 4.96%, 7.08%, 14.11%, respectively ( Figure 5) .
Effect of rmh TRAIL on normal cell types To test whether rmh TRAIL initiates apoptosis in normal cells, 9 lines of normal cells, were exposed to rmh TRAIL (1 ng/mL-10 µg/mL) or wt TRAIL (1 ng/mL-10 µg/mL) for 24 h. No morphological evidence of apoptosis was observed as induced by rmh TRAIL (except for HL-7702); in addition, there was no decreased cell viability in staining of the cells by MTT ( Figure  6 ), which indicated that rmh TRAIL was not cytotoxic toward these normal cell types. There was mild injury on HL-7702 hepatocytes elicited by both rmh TRAIL and wt TRAIL, and no cytotoxicity on CCC-HEL-1, human primary embryo liver-derived cells (Figure 6 ). The IC 50 of rmh TRAIL and wt D 0 , the day of the start of treatment; D n , the day of the end of the experiments, which was after a 10 day treatment and a 14 day withdrawal. rmh TRAIL, recombinant mutant human TRAIL; wt TRAIL, wild type TRAIL. TRAIL on HL-7702 exceeded 10 µg/mL.
Discussion
Although TNF and FasL have potent cytotoxic activity against many types of tumor cells, the application of these death ligands to cancer therapy has been restricted by their severe toxicity to normal tissues. The discovery of TRAIL as a death ligand, with its wide tissue-mRNA distribution and its unique receptor system, suggests that this ligand might be more suitable than TNF or FasL for systemic cancer therapy.
rmh TRAIL, developed by Beijing Sunbio Biotech, is a mutant form of human native TRAIL, but the functional sequences are conservative. Native TRAIL is expressed as a type II transmembrane protein that can be cleaved proteolytically to form a soluble homotrimer [7, 8] . The therapeutic potential of a recombinant soluble version of human TRAIL that can be produced in E coli and purified as a 60-kDa homotrimer has been evaluated [9, 11] . An optimized antineoplastic agent can selectively induce apoptosis of cancer cells while sparing normal cells. Some scientists have oppugned the safety of TRAIL on hepatocytes [22, 23] . To obtain a form of TRAIL that has higher antitumor activity and safety, Beijing Sunbio Biotech produced rmh TRAIL with a circular permuted extracellular sequence of native human Apo2L/TRAIL. Our previous work revealed that rmh TRAIL had a high affinity for its death receptors and water-solubility (data not shown). This molecule forms more stable homotrimers. The pharmacokinetics research of rmh TRAIL indicates that the concentration in tumor tissue was higher than that in plasma. Furthermore, rmh TRAIL was more resistant to trypsin proteolysis in vitro than wt TRAIL (data not shown). All of the above suggests that rmh TRAIL could contribute to long-standing antitumor activity.
The present study first assesses the antitumor activity of rmh TRAIL in vitro. A spectrum of cancer cell lines exhibited sensitivity in vitro to rmh TRAIL. This finding is consistent with previous reports that native TRAIL is cytotoxic toward cell lines from cancers of the lung, colon, and breast [9] [10] [11] . rmh TRAIL triggers more cell death in vitro than wt TRAIL. The study of NCI-H460 xenograft models indicates that rmh TRAIL can cause tumor regression or suppress tumor growth, and can initiate tumor cell apoptosis, which is consistent with its apoptosis-inducing activity in vitro. The antitumor activity of TRAIL after ip administration has been demonstrated in several mouse xenograft models of human cancers, including colorectal [9] , breast [11] , and glioma [24] . rmh TRAIL caused a dose-dependent suppression of tumor growth, and 15 mg/kg rmh TRAIL resulted in a 86.7% reduction in mean tumor volume, whereas wt TRAIL only caused a 25.7% reduction using the same dose. Therefore, in the present study, the antitumor activity of rmh TRAIL is higher than that of wt TRAIL in the experiments both in vivo and in vitro. Compared with wt TRAL, rmh TRAIL can achieve same antitumor activity under lower dosages.
Second, rmh TRAIL induced apoptosis in NCI-H460 was confirmed by cell death ELISA assay, TUNEL assay, and flow cytometry. Nucleus condensation, apoptotic body appearance, and DNA fragmentation are universal characteristics in the cells undergoing apoptosis. Furthermore, cell death ELISA assay and flow cytometry showed the quantity of apoptotic cells. From the evidence in the present study, it is elicited that rmh TRAIL could induce NCI-H460 apoptosis, that and it is time-and concentration-dependent. Third, MTT assay was used to examine the cytotoxicity effect of rmh TRAIL on normal cells. Although rmh TRAIL was cytotoxic toward many tumor cell lines in vitro, rmh TRAIL showed no inhibition on normal cells tested in the experiment from endothelial, fibroblastic, myocardial, cutaneous, lung, renal, and tracheal origin, supporting the notion that rmh TRAIL dose did not increase cytotoxicity to generally nontransformed cells. The results are consistent with Ashkenazi et al [9, 10, 25, 26] . rmh TRAIL and wt TRAIL showed mild cytotoxicity to HL-7702 cells, which are separated from adult liver. The IC 50 of rmh TRAIL exceeded 10 µg/mL. The IC 50 for non-small cell lung cancer and colonic cancer, the main clinical indications, are all 0.01 µg/mL, which is at least 1000 times lower than the IC 50 for HL-7702. Furthermore, the pharmacokinetics research on nonhuman primates (cynomolgus monkeys) indicated that the maximal plasma concentration (C max ) of rmh TRAIL (iv, 5 mg/kg) was 25 µg/mL (data not shown). The dose used in humans would be no more than 5 mg/kg. Therefore, the C max will be no more than 25 µg/mL, which is less than the IC 50 of HL-7702. The results suggest that the clinical effective dose of rmh TRAIL might be safety for human.
In conclusion, rmh TRAIL provided potent antitumor activity in vitro and in vivo, although it did not exert obvious cytotoxicity on a wide variety of normal cells. Therefore, rmh TRAIL might prove to be a useful new agent in fighting cancer cells, leaving normal cells unharmed. Figure 6 . Effect of rmh TRAIL or wt TRAIL on proliferation in normal cell lines. Cells were incubated with serial dilutions of recombinant mutant human (rmh) TRAIL (1 ng/mL-10 µg/mL) or wild type (wt) TRAIL (1 ng/mL-10 µg/mL) for 24 h, and cell growth relative to medium controls was determined by MTT assay.
